Analysts think CRVO stock price could increase by 394%
Aug 01, 2024, 6:26 AM
40.49%
What does CRVO do
CervoMed Inc., originally Diffusion Pharmaceuticals Inc., is a clinical-stage biotech firm based in Boston, focusing on CNS therapeutics including neflamapimod for neurodegenerative diseases like DLB and Alzheimer's. Incorporated in 2016, the company employs 13 people and its lead product, neflamapimod, is currently in a Phase IIb clinical trial.
6 analysts think CRVO stock price will increase by 393.61%. The current median analyst target is $65.28 compared to a current stock price of $13.22. The lowest analysts target is $30.30 and the highest analyst target is $73.50.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
